Bank of America Securities analyst Sachin Jain has reiterated their bullish stance on AZN stock, giving a Buy rating on September 30. Sachin ...

Owkin has partnered with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer. Takeaway Points Owkin has ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

The Israeli-American unicorn company ImmunAI has signed a multi-year cooperation agreement with the pharmaceutical giant ...

AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has accepted the supplemental biologics license application ...

AstraZeneca (NASDAQ:AZN) and partner Daiichi Sanyko (OTCPK:DSKYF)(OTCPK:DSNKY) said the FDA has accepted their application ...

(Reuters) - AstraZeneca will pay $18 million to biotechnology firm Immunai Inc to use the New York-based firm's AI model of ...

Santa Barbara, Calif.– 2024 October 2 –Rupa Dainer, MD, U.S. Navy veteran and medical director, senior patient safety physician of ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and ...

The solution will use Owkin's data network and artificial intelligence to pre-screen for gBRCA mutations in breast cancer directly from digital pathology slides.

AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...